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Smuary Tumour necrosis factor a (TNF-a) is a cytokine with a variety of immunological properties. The
identification of two receptors for this molecule, i.e. the 75 kDa and the 55 kDa TNF receptors (TNF-R),
recently clarified the mechanisms through which this cytokine provides its wide range of immunomodulatory
activities. In this study we have investigated the expression and the functional properties of these receptors on
tumour-infiltrating lymphocytes (TILs) recovered from 17 patients with solid cancers (melanoma. colorectal
carcinoma and lung cancer). To this end, TIL lines and freshly isolated TILs were evaluated for (a) the
expression and the functional role of TNF receptors following culture in the presence of interleukin 2 (IL-2)
and (b) the production of TNF-a following culture with IL-2 and the role of this cytokine in IL-2-driven TIL
proliferation. Flow cytometry analysis demonstrated that TILs bear the 75 kDa TNF-R. Moreover, TIL lines
express detectable messages for TNF-a and release this cytokine. Functional in vitro studies have shown that
anti-TNF-a, as well as anti-75 kDa TNF-R antibodies, are able to inhibit the IL-2-induced TIL proliferation.
These data demonstrate that TILs are equipped with a fully functional TNF-R system and suggest a putative
role for this receptor and its ligand in the activation and expansion of TILs following immunotherapy with
IL-2.
Keywords: TIL; TNF receptors; IL-2-driven growth
Tumour-infiltrating lymphocytes (TILs) have been extensively
studied over the last few years both in vitro and in vivo for
their potent anti-tumour activity (Itoh et al., 1986; Muul et
al., 1987; Rosenberg et al., 1988; Kradin et al., 1989). It has
been demonstrated that they might control tumour growth
by mediating a large spectrum of functional activities includ-
ing cytotoxicity, cytokine release, helper and suppressor
activities or a combination of these effects (Itoh et al., 1986;
Topalian et al., 1989; Balch et al., 1990; Kim et al., 1990;
Pandolfi et al., 1991). Human TILs have been derived from a
variety of solid tumours in the presence of several cytokines,
including inter}eukcin 2 (IL-2) and interleukin 4 (IL-4).
Although many data are now available regarding the ability
of TILs to control tumour growth, the mechanisms accoun-
ting for their in vitro and possibly in vivo proliferation are
still largely unknown (Kawakami et al., 1988; Yagita et al.,
1989; Shimuzu et al., 1991).
TNF-a provides a wide spectrum of immunoregulatory
activities on several cell types, including B, T and NK lym-
phocytes, monocytes and polymorphonuclear cels (Shalaby
et al., 1985; Philip and Epstein, 1986; Ostensen et al., 1987;
Ranges et al., 1987; Blay et al., 1989). Among these, TNF-e
has been observed to play a role in T-cell proliferation
(Nedwin et al., 1985; Scheurich et al., 1987; Robinet et al.,
1990), thus providing a co-stimulatory proliferative signal.
The production of TNF-x and the expression of its specific
receptors may be regulated by IL-2. The finding that these
cytokines (TNF-a and IL-2) have synergistic effects on T-cell
proliferation (Scheurich et al., 1987) suggests that TNF-a
may function as an autocrine/paracrine growth factor for T
cells. TNF-( mediates its biological activity through two
specific membrane receptors, which have been recently
identified and cloned: type 1 TNF-R of 55-60 kDa and type
2 TNF-R of 75-80kDa (Imamura et al., 1988; Gray et al.,
1990; Kohno et al., 1990; Loetscher et al., 1990; Schall et al.,
1990; Smith et al., 1990; Lewis et al., 1991). Although the
extracellular regions of the two TNF receptors share approx-
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imately 30% amino acid identity, the two TNF-Rs are un-
related in their cytoplasmic domains, thus suggesting that
these receptor structures are involved in distinct signal trans-
duction pathways. The generation of specific monoclonal
antibodies (MAbs) which recognise the 55 kDa and 75 kDa
TNF-Rs (Brock.haus et al., 1990) has recently allowed a
better understanding of the role of TNFU- and its receptors
on T cells (Scheurich et al.. 1987; Andrews et al., 1990: Ware
et al., 1991).
This study was undertaken to investigate the expression of
TNF receptors and their functional role on TILs growing in
the presence of IL-2. For this purpose, freshly isolated TILs
and TIL lines were evaluated for (a) the expression and the
functional role of TNF receptors and (b) the production of
TNF-x following culture with IL-2 and the role of this
cytokine in IL-2-driven TIL proliferation.
Materials and methods
TIL isolation andexpansion
TIL lines were derived from surgical specimens of 13 patients
with solid tumours (five with primary colorectal carcinoma,
four with hepatic metastases from colorectal cancer and four
with primary melanoma). Tumour samples were washed with
RPMI-1640 (Gibco, Paisley, UK) medium to mininise pos-
sible peripheral blood lymphocyte (PBL) contamination in
the TIL preparations and were successively cut into 1 mm
fragments. The fragments were cultured in RPMI-1640 con-
taining 10% FCS (ICN, Oxnard, CA, USA). 100 U m-'
recombinant IL-2 (kdndly supplied by Biogen, Cambridge,
MA, USA), 50UmlJ' penicillin, 50 igml' streptomycin,
50 ug ml-' gentamicin and 200 ng ml-' fungizone. In 9 of 13
patients (1-9), TIL cultures were expanded in the presence of
IL-2 for 2 days and restimulated with phytohaemagglutinin
(PHA) (0.1 Lgml-') and irradiated feeders (normal PBL).
Twelve hours after the restimulation, medium was almost
completely removed from the wells and was replaced with
RPMI-1640 containing IL-2 only. All studies were performed
14-18 days after the restimulation. In 4 of 13 patients
(10-13), TIL lines were derived in the presence of IL-2
(100 U ml-') only.TN mc T - n
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In four patients (two with lung cancer and two with col-
orectal cancer), freshly isolated TILs were obtained following
digestion in RPMI-1640 medium supplemented with 10%
FCS, 0.1% collanase type IV (Sigma, St Louis, MO,
USA), 0.002% DNAse type 1 (Sigma) and 0.01% hyaluro-
nidase type V (Sigma) for 1-2h at 37C. Cell suspensions
containing both TILs and tumour cells were washed and
passed through a surgial gauze. TlLs were purified by roset-
ting the cell suspension with neuraminidase (Sigma)-treated
sheep red blood cells (SRBCs) followed by repeated Ficoll/
Hypaque gradient separations as previously described in
detail (Trentin et al., 1990). The majority of rosetting cells
(>95%) obtained with this procedure were T lymphocytes,
and more than 90% were viable as judged by the trypan blue
exclusion test.
Monoclonal antibodies andflow cytometry analysis
TILs were characterised by different groups of MAbs, most
of them belonging to the OK (Ortho Pharmaceutials,
Raritan, NJ, USA) and Leu (Becton Dickinson, Sunnyvale,
CA, USA) series, including those belonging to CD3 (Leu4,
OKT3), CD4 (Leu 3, OKT4), CD8 (Leu 2, OKT8), CD56
(Leu 19). The specificity of these reagents has been reported
in detail (Knapp et al., 1989). To characterise the expression
of TNF-R(s) on TIL, before performing the phenotypical
study, cells were washed in 40 mM citrate containing 140 mm
sodium chloride (pH 4) to remove cell-bound TNF, as des-
cribed in detail by Zambello et al. (1990). The following
MAbs were used; the utr-I and the htr-9 MAbs (Brockhaus
et al., 1990) (kindly provided in PBS buffer by Dr M Brock-
haus, Basle, Switzerland) which recognise the 75 kDa and
55 kDa TNF-R, respectively, and followed by an incubation
with F(ab)2 goat anti-mouse (Technogenetics, Turin, Italy),
as previously described (Trentin et al., 1990). Both antibodies
have previously been observed to work in different experi-
mental conditions, including on B, T and granular lym-
phocytes (Zambello et al., 1992; Trentin et al., 1993).
Controls for flow cytometric analysis were performed using
isotype control antibodies.
The expression of TNF receptors on TILs was also inves-
tigated by evaluating the binding of phycoerythrin (PE)-
TNF-x on the cell surface using a flow cytometer. Briefly,
10g±l of PE-TNF-x (10 Lgml-') was added to 10' cells and
the mixture was incubated for 60 min on ice. Cells were then
washed twice and resuspended in 0.2 ml of PBS for flow
cytometric analysis. As controls for the FACS analysis, cells
were incubated with avidin-PE. The lymphocytes were
analysed as indicated below. Blocking expermnents were car-
ried out by pretreating the cells for I h at 4-C with the
following antibodies: 20pgml utr-I and 20#gml-' htr-9
for TNF-z binding. After washing, the cells were incubated
with PE-TNF-4 as reported above. Ten thousand cells bear-
ing the typical lymphocyte scatter were scored.
Northern blot analysis
Total cllular RNA was extrcted from 10 x 10' TILs after
lysis with 4 M gaidine isothiocyanate and by centrifation
through a 5.7 M caesium chloride gradient Between 5 and
O OLg of each sample was denatured at 65C for IOmin in an
electrophoresis buffer (20 mM morpholinopropane sulphonic
acid, 6.5% formaldehyde, 50% formamide, 0.05 mg m1'
ethidium bromide), size fractionated by electrophoresing on
1.0% agarose gel containing 6.5% formaldehyde, then trans-
ferred to nylon filters. Filters were dried, soaked in 0.05 M
sodium hydroxide for 5 minm prehybridised at 42-C for 6 h
with a prehybridisation solution (50% formamide 5 x Den-
hardt's solution, 0.1I% SDS, 100 mgml-' denatured salmon
sperm DNA) and hybridised at 42-C for 15h in the same
solution containing the 3P random primed labelld probe.
The message for TNF-a was detected as 1.6 kb size mRNA
by hybridisation with a cDNA fragment subcloned into a
pUC vector kindly provided by Genentech (South San Fran-
cisco, CA, USA). After hybridisation, filters were washed
twice in 2 x SSC with 0.5% SDS and twice in 0.1 x SSC with
0.1% SDS at 65C. Filters were exposed for 1-5 days at
- 80'C to Kodak X-OMAT XAR-5 films. Rehybridisation
of the filters with actin probe was performed after washing
the membrane for 2h at 85C in 20mM Tris-HCI, 0.1%
SDS.
Culture conditions
TIL were cultured in 96-well round-bottom plates (Titertek,
ICN, Oxnard, CA, USA) in RPMI-1640 medium supp-
emented with 10% FCS (ICN), picilin (50 Uml-'), strp-
tomyran (50 gm'). Cltures were carrie out in tripliate,
with each well containing lx 101 cells in 0.2 ml of medium
and were incubated for 2 days at 37C in a humidified
atmosphere of 5% carbon dioxide and 95% air. Recom-
binant IL-2 was added at the beginning of the culture at
different concentrations (10, 100, 100OUml-'). In order to
block the IL-2-induced effects, the cells were cultured for
30min with utr-l (I0pgnml-1) MAb or control isotype-
matched IgG at the beginning of the culture at 4-C before
adding IL-2. Rabbit anti-human TNF-x polyclonal antibody
(purchased in PBS buffer from Janssen Bioch, Geel, Belgium)
was also used. This reagent has been provided to block the in
vitro activity of TNF-a. The proliferation was determined by
pulsing plates with 1 pCi per well of[3HVthymidine (3H-TdR,
CEA Ire Sorin, Saluggia, Italy) for the last 12 h of culture;
cells were then harvested and 3H-TdR incorporation
measured in a a-scintillation counter. The results of the
proliferation assay in the presence of different antibodies
were calculated and expressed as a percentage of inhibition
according to the following formula: (1- c.p.m. in the
presence of the stimulus and antibody/c.p.m. in the presence
of the stimulus) x 100. The results are expressed as
mean ± s.d.; comparisons between values were made using
the t-test. P<0.05 was considered sipificant.
TNFa assay
The presewne ofTNF-x in the 13 culture supernatants ofcells
grown at a concentration of 1 x IOml-' in 24-well plates in
the presence of IL-2 (l00Uml-') and 14-18 days after the
restimulation was analysed using an immunoenzymatic assay.
This was based on two mouse non-cross-reacting IgGl MAbs
(B154.9 and B154.7, kindly provided by Dr G Trinchieri, the
Wistar Institute, Philadelphia, PA, USA) (Cuturi et al.,
1987), directed against two distin determinants of TNF-a.
One of these (B154.7 MAb) was coupled to alkalin phos-
phatase according to standard protocols. An enzyme-linked
immunosorbent assay (ELISA) amplfication system (Immuno
Sekct, Gibco BRL) was also used to enhance the TNF-x
detection limit, which in the final assay was 50 pgml-'. Data
are expressed as mean ± s.d.
Res
The data of the phenotypic analysis are reported in Table I:
all our cell lines (1-13) as well as freshly isolated TILs
(14-17) were CD3 positive, while CD4 and CD8 antigens
were heterogenously represented.
Bining ofTNF-R antibodies and PE-TNF-x to TILs
Flow cytometry analysis showed that the 75 kDa TNF-R,
but not the 55 kDa TNF-R, was expressed on TIL lines. The
pattern of expression of TNF receptors in two representative
TIL lines is reported in Figure la and b. T-he histograms of
75 kDa TNF-R, rnised by utr-l MAb, were totally
shifted to the right as compared with the control histogram
and the htr-9 histogramlThis pattern indicates that EL-2
cultured TILs expre the 75 kDa TNF-R.
The analyss of TNF receptors on freshly isolted TILs is
reported in Figure lc and d and demonstrates that firshly
isolated TT s also express the 75 kDa TNF-R. Blocking
241TNFmcspos an TILgood
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experiments of PE-TNF-x binding with these antibodies
(utr-l and htr-9) were also performed. TILs treated with
these antibodies (Figure le and f) demonstrated that utr-l
MAb almost completely blocks the binding of TNF-c to
TILs, while htr-9 MAb does not affect the binding of TNF-(
to these cells to a substantial extent. The histogram obtained
Table I Phenotypic analysis and cytotoxic function of tumour-
infiltrating lymphocytese
Surface phenotype (%}
Patients CD3 CD4 CD8 CD56
1 98 41 58 28
2 99 58 41 9
3 98 54 34 1
4 99 40 62 10
5 99 59 35 18
6 99 22 75 nd
7 99 16 83 27
8 98 75 18 21
9 99 10 85 13
10 89 21 61 15
11 93 29 66 4
12 99 36 63 28
13 99 36 63 28
14 95 26 66 7
15 94 53 41 18
16 91 34 68 10
17 90 48 38 21
aA lines express the 75kDa TNF receptor; TNF-z mRNA was







following the block with utr-l and htr-9 MAbs was superim-
posable on that obtained in the control experiment (data not
shown).
Evaluation ofmRNA transcriptsfor TNF-<x
To address the issue of whether IL-2-induced TIL prolifera-
tion is mediated by the release of TNF-c, we evaluated the
ability ofTILs to produce TNF-x and the role ofanti-TNF-x
antibody in IL-2-driven TIL proliferation. As shown in
Figure 2, TIL lines obtained from five representative patients
expressed a detectable message for TNF-ax, thus indicating
that this molecule is constitutively expressed in TILs cultured
with IL-2. Detectable levels of TNF--a were also demon-
strated in the supernatants obtained from all 13 TIL lines
cultured in the presence of IL-2 (mean of all 13 lines
376.5 ± 159.9 pg ml-'). Owing to the low numbers of cells
recovered, a Northern blot was not performed on freshly
isolated TILs.
Role of TNF-x and its receptors in IL-2-induced TIL growsth
Since TILs express the 75 kDa TNF-R and release TNF-x
after in vitro culture with IL-2, in order to determine whether
TNF-a and the 75 kDa TNF-R were involved in the pro-
liferation induced by IL-2 TIL lines were cultured with
different concentrations of IL-2 (10, 10 0, 1000 U ml-') in the
presence or absence of anti-75 kDa TNF-R MAb and anti-
TNF-x polyclonal antibody. All the TIL lines tested
significntly proliferated in response to low and high concen-
Log fluorescence intensity
Figwe I Immunofluorescent flow cytometnrc analysis of TNF receptors on two TIL lines (a and b) and on freshly isolated TILs
from two patients (c and d) and assessment of PE-TNF-x binding (e and f) on two representative TIL lines. Relative cell number
is indicated on the ordinate. The histograms of utr-l- and htr-9-stained cells were superimposed on the histogram of control
IgG-stained cells (indicated by control). Marker was set up to include >95% of the control IgG-stained cells. e and f, Effects of
pretreatment with control IgG, utr-I and htr-9 MAbs on PE-TNF-a binding. TILs were pretreated with 20jtgml-' utr-l and
20 ugm1-' htr-9 before staining with PE-TNF-m. The staining with PE-TNF-z alone and with control IgG plus streptavidin
(SA)-PE reagent alone is shown.
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Figure 2 Northern blot analysis of the expression of TNF-x in
total RNA extracted from five TIL lines isolated from five
patients with solid tumours (indicated as 1-5). Ten micrograms
of total RNA were loaded per lane. The amount of loaded total
RNA is shown following hybridisation for actin. The size of the






IL-2 concentrations (U ml ')
Fire 3 Effects of anti-TNF-a polyclonal antibody and anti-
75 kDa TNF-R MAb on IL-2-dnrven proliferation of 13 TIL
lines. TILs were cultured in the presence of different concentra-
tions of IL-2 (10. 100 and 1000 Uml-') and in the presence of
the above reported antibodies. The data are expressed as
means ± s.d. percentage inhibition with respect to 3H-TdR incor-
poration by TILs cultured with IL-2 alone. -, utr-l MAb;
E. anti-TNF-a Ab: L. control Ab.
trations of IL-2 (c.p.m. 16 500 ± 1208, 48 320 ± 6240,
56 430 ± 3480 at 10, 100 and 1000 U ml-' IL-2, respectively).
These data are consistent with the phenotypic findings that
these cells are equipped with a high-affinity IL-2R complex
(Trentin et al., 1994). When TIL lines were grown in the
presence of different concentrations of IL-2 and anti-TNF-a
antibodies (Figure 3) a discrete inhibitory effect was observed
in the presence of this antibody, while control isotype
antibody did not show any effects on IL-2-driven growth.
The difference in percentage inhibition between anti-TNF-a
MAb and control MAb was statistically significant (P<
0.05). Proliferation assays following culture of TIL lines in
IL-2 concentrations (U ml-1)
Figre 4 Effects of anti-TNF-a polyclonal antibody and anti-
75 kDa TNF-R MAb on IL-2-driven proliferation of freshly
isolated TILs from a patient with lung cancer. TILs were cultured
in the presence of different concentrations of IL-2 (10, 100 and
1000 U ml-') and in the presence of the above reported
antibodies. The data are expressed as percentage inhibition of
triplicate exeperiments with respect to the 3H-TdR incorporation
by TILs cultured with IL-2 alone. _, utr-l MAb; 0, anti-
TNF-a Ab; = . control Ab.
the presence of different IL-2 concentrations and anti-75 kDa
TNF-R MAb showed that utr-l MAb was able to inhibit
IL-2-driven TIL proliferation to different degrees (Figure 3),
while control antibody did not (P<0.05). Repetitive
experiments showed consistent results.
Freshly isolated TILs obtained from four patients were
cultured in the same experimental conditions. The effect of
anti-75 kDa TNF-R and anti-TNF-a antibodies in one
representative subject is reported in Figure 4. Freshly isolated
TILs did not proliferate in response to different concentra-
tions of IL-2 as well as TIL lines (c.p.m. 6523 ± 308,
8305 954, 21 308± 2154 at 10, 100 and 1000 U ml-' IL-2
respectively). When freshly isolated TILs were cultured in the
presence of IL-2, both anti-75 kDa TNF-R MAb and polyc-
lonal anti-TNF-a antibody displayed a decrease in the IL-2
mediated proliferation.
Dicussos
Our data demonstrate that TILs express the 75 kIDa TNF
receptor. Blocking this receptor resulted in an inhibition of
TIL proliferation induced by IL-2. This suggests that TNF-R
delivers a proliferative signal in TILs and that this effect is
mediated by endogenously induced TNF-a following culture
of TIL with IL-2, as demonstrated by Northern blot and
ELISA analyses.
Although TILs have been reported to produce TNF-a
(Beildegrun et al., 1989; Wang et al., 1989; Vaccarello et al.,
1990; Ioannides et al., 1992) and this cytokine has been
demonstrated to potentiate the lytic machinery of cytotoxic
cells (Ostensen et al., 1987; Ranges et al., 1987; Espevik et
al., 1988; Blay et al., 1989; Naume et al., 1991), no inform-
ation was available on the mechanisms used by TNF-a to
deliver a proliferation signal to TILs. Our results confirm
that TNF-a is constitutively expressed and released in TIL
lines cultured with IL-2 and demonstrate that these cells bear
the 75 kDa TNF receptor. Furthermore, our data clearly
point to a specific role of TNF-c on TIL growth since
anti-TNF-a and anti-TNF-R antibodies inhibit the IL-2-
induced TIL proliferation. These observations suggest that
I NF-aTNFrSW niL oh
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TILs might use their own secreted TNF-a in an autocrine/
paracrine network. These observations are strengthened by
the demonstration that freshly isolated TILs also bear TNF
receptors (75 kDa) and that its blocking and/or adding anti-
TNF-a antibody results in a decrease of IL-2-driven TIL
proliferation.
To address the question of the specific surface structures
involved in the transduction of the proliferative signal by
endogenously produced TNF-m, TILs were evaluated for the
presence of different TNF-Rs using MAbs that specifically
recognise TNF receptors. Our results demonstrate that the
75 kDa TNF-R is expressed on the surface membrane of
freshly isolated and cultured TILs, while the 55 kDa TNF-R
was lacking on the same cells. In addition, the anti-75 kDa
TNF-R antibody has been shown to affect the binding of
PE-TNF-(. In view of the consideration that TNF-x induces
a wide spectrum of activities, it is likely that some of these
functions are independently mediated by one of the two
receptors. In fact, the 55 kDa TNF-R has been observed to
trigger cytotoxicity, the proliferation of fibroblasts and the
synthesis of prostaglandin E2, while the 75 kDa TNF-R
delivers the signal for T-cell proliferation (Englemann et al.,
1990; Espevik et al., 1990; Tartaglia et al., 1991). Our obser-
vation that anti-75 kDa TNF-R antibody inhibits TIL pro-
liferation suggests that this structure is involved in the in
vitro TIL growth.
Our finding that TIL lines and freshly isolated TILs grow
in the presence of IL-2 and express functional TNF receptors
suggests that IL-2 might up-regulate the expression of this
receptor, similar to what has been observed on cultured T
cells obtained from peripheral blood (Ware et al., 1991). The
evidence that TNF-a up-regulates the expression of IL-2
receptors (Scheurich et al., 1987; Chouaib et al., 1988)
indicates that the expression of these receptors (both IL-2
and TNF receptors) and the effect of these cytokines on T
cells are likely to be closely related.
In as much as it has been extensively reported that TNF-a
exhibits cytotoxic effects, the possible role of this cytokine in
the control of tumour growth in neoplastic patients deserves
comment. Results reported in this manuscript coupled with
the observation that TILs release TNF-a following auto-
logous tumour stimulation (Schwartzentruber et al., 1991)
highlight the role of this cytokine on the mechanism leading
to the expansion and function of TILs. Moreover, the
therapeutic efficacy of these cells on clinical grounds might be
related to the role of TNF-a not only via a direct cytotoxic
mechanism but also favouring the accumulation of relevant
T-cell subsets at the site of tumour growth in vivo.
Abhrvistiom: TIL, tumour-infiltratig lymphocyte; TNF-o, tumour
necrosis factor a, TNF-R, tumour necrosis factor receptor, PBL,
peripheral blood lymphocyte; PE, phycoerythrin.
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